New allelic arrangement CYP2D6*36x2 found in a Japanese poor metabolizer of debrisoquine

被引:19
作者
Chida, M
Ariyoshi, N
Yokoi, T
Nemoto, N
Inaba, M
Kinoshita, M
Kamataki, T
机构
[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Drug Metab, Div Pharmacobiodynam, Sapporo, Hokkaido, Japan
[2] Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Toxicol, Toyama, Japan
[3] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan
[4] Otsuka Pharmaceut Co Ltd, Tokushima 77101, Japan
来源
PHARMACOGENETICS | 2002年 / 12卷 / 08期
关键词
CYP2D6*10; gene duplication; genotype;
D O I
10.1097/00008571-200211000-00011
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
[No abstract available]
引用
收藏
页码:659 / 662
页数:4
相关论文
共 50 条
  • [41] CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial
    Smith, D. Max
    Weitzel, Kristin W.
    Elsey, Amanda R.
    Langaee, Taimour
    Gong, Yan
    Wake, Dyson T.
    Duong, Benjamin Q.
    Hagen, Melanie
    Harle, Christopher A.
    Mercado, Elvira
    Nagoshi, Ying
    Newsom, Kimberly
    Wright, Ashleigh
    Rosenberg, Eric, I
    Starostik, Petr
    Clare-Salzler, Michael J.
    Schmidt, Siegfried O.
    Fillingim, Roger B.
    Johnson, Julie A.
    Cavallari, Larisa H.
    [J]. GENETICS IN MEDICINE, 2019, 21 (08) : 1842 - 1850
  • [42] Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia
    Doki, Kosuke
    Homma, Masato
    Kuga, Keisuke
    Kusano, Kazutomi
    Watanabe, Shigeyuki
    Yamaguchi, Iwao
    Kohda, Yukinao
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (11) : 919 - 926
  • [43] Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia
    Kosuke Doki
    Masato Homma
    Keisuke Kuga
    Kazutomi Kusano
    Shigeyuki Watanabe
    Iwao Yamaguchi
    Yukinao Kohda
    [J]. European Journal of Clinical Pharmacology, 2006, 62 : 919 - 926
  • [44] The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients
    Ueda, M
    Hirokane, G
    Morita, S
    Okawa, M
    Watanabe, T
    Akiyama, K
    Shimoda, K
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (03) : 486 - 491
  • [45] Evaluating the impact of missenses mutations in CYP2D6*7 and CYP2D6*14A: does it compromise tamoxifen metabolism?
    Borba, Maria A. C. S. M.
    Melo-Neto, Renato P.
    Leitao, Glauber M.
    Castelletti, Carlos H. M.
    Lima-Filho, Jose L.
    Martins, Danyelly B. G.
    [J]. PHARMACOGENOMICS, 2016, 17 (06) : 561 - 570
  • [46] Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6
    Desai, M
    Tanus-Santos, JE
    Li, L
    Gorski, JC
    Arefayene, M
    Liu, Y
    Desta, Z
    Flockhart, DA
    [J]. PHARMACOGENOMICS JOURNAL, 2003, 3 (02) : 105 - 113
  • [47] Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype
    Mannheimer, Buster
    Haslemo, Tore
    Lindh, Jonatan D.
    Eliasson, Erik
    Molden, Espen
    [J]. THERAPEUTIC DRUG MONITORING, 2016, 38 (01) : 127 - 134
  • [48] The Associations Between CYP2D6 Metabolizer Status and Pharmacokinetics and Clinical Outcomes of Venlafaxine: A Systematic Review and Meta-Analysis
    Lin, Xiao-Qian
    Wang, Ping
    Cai, Wen-Ke
    Xu, Gui-Li
    Yang, Mei
    Zhou, Meng-Di
    Sun, Mei
    He, Fang
    He, Gong-Hao
    [J]. PHARMACOPSYCHIATRY, 2019, 52 (05) : 222 - 231
  • [49] Functional characterization of CYP2D6 enhancer polymorphisms
    Wang, Danxin
    Papp, Audrey C.
    Sun, Xiaochun
    [J]. HUMAN MOLECULAR GENETICS, 2015, 24 (06) : 1556 - 1562
  • [50] CYP2D6, serotonin, and suicide-a relationship?
    Bertilsson, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (03) : 304 - 305